Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Open accessAbstract
An engineered cancer immunotherapy using a collagen-binding domain enhances efficacy and reduces adverse events.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combination treatment with CPI and IL-2 resulted in complete elimination of tumors in 9 of 13 animals bearing orthotopic breast cancer.
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
The Results section distinguishes the two combinations: CBD-CPI plus CBD-IL-2 produced complete remission in 9 of 13 mice with MMTV-PyMT breast tumors, whereas unmodified CPI plus IL-2 did so in only 1 of 13. The cited sentence assigns the 9-of-13 result to CPI plus IL-2 without the essential CBD modification. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredConjugating immune checkpoint inhibitors anti-CTLA4 and anti-PD-L1 plus IL-2 to the collagen-binding domain of VWF A3 domain reduced side effects.
“immune checkpoint inhibitors (antibodies) including anti-CTLA4 and anti-PD-L1 plus IL-2 were conjugated to the collagen-binding domain of the blood protein von willebrand factor (VWF) A3 domain to reduce side effects.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
The Results section (page unavailable) reports reduced toxicity for the collagen-binding-domain-modified checkpoint antibodies and IL-2 in mice. However, the paper specifies that the antibodies were conjugated to the domain, whereas IL-2 was joined by recombinant fusion—not conjugation as the citing sentence states. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThis formulation allowed drug targets to bind to tumor stroma to exert local effects and gained a promising efficacy and safety profile compared to unconjugated molecules in several mouse models.
“This formulation allowed drug targets to bind to the tumor stroma to exert their effects locally and gained a promising efficacy and safety profile compared to the unconjugated molecules tested in several mouse models.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · see citing works
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,827 · see citing works
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S. F., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653 · see citing works
Ricard-Blum, S. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004978 · Cited by 2,305 · see citing works
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867 · see citing works
Alsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,715 · see citing works
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3156 · Cited by 1,656 · see citing works
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works
Collagen density promotes mammary tumor initiation and progression
Provenzano, P. P., Inman, D. R., Eliceiri, K. W., Knittel, J. G., Yan, L., Rueden, C., White, J. G., & Keely, P. J. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-11 · Cited by 1,364 · see citing works
Rosenberg, S. A. (1994) · JAMA · doi:10.1001/jama.1994.03510360033032 · Cited by 1,100 · see citing works
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1× · see citing works
“As a consequence, CBD-CPI treatment enhanced effector (CD62L−CD44+) CD8+ T cell–to-Treg ratios within the tumor, a predictor of therapeutic efficacy (32), compared to equidosed unmodified CPI and PBS treatments (Fig.”
BackgroundWhy are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611 · see citing works
Interstitial Flow and Its Effects in Soft Tissues
Swartz, M. A., & Fleury, M. E. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151850 · Cited by 589 · see citing works
Self-citationRole of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 551 · see citing works
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545 · see citing works
Kufe, D. W. (2012) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 440 · see citing works
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433 · see citing works
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381 · see citing works
Mach, J. P., Buchegger, F., Forni, M., Ritschard, J., Berche, C., Lumbroso, J.-D., Schreyer, M., Girardet, C., Accolla, R. S., & Carrel, S. (1981) · Immunology Today · doi:10.1016/0167-5699(81)90011-6 · Cited by 376 · see citing works
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335 · see citing works
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31043 · Cited by 328 · see citing works
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S. R., Donia, M., & Straten, P. T. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 309 · see citing works
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 294 · see citing works
Glycoprotein VI–dependent and –independent pathways of thrombus formation in vivo
Dubois, C., Panicot‐Dubois, L., Merrill‐Skoloff, G., Furie, B., & Furie, B. C. (2006) · Blood · doi:10.1182/blood-2005-09-3687 · Cited by 236 · see citing works
Immune Checkpoint Blockade in Cancer Therapy
Allison, J. P. (2015) · JAMA · doi:10.1001/jama.2015.11929 · Cited by 213 · see citing works
Extracellular Matrix Proteins in Hemostasis and ThrombosisPreprint
Bergmeier, W., & Hynes, R. O. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005132 · Cited by 182 · see citing works
The role of blood platelets in tumor angiogenesis
Sabrkhany, S., Griffioen, A. W., & Egbrink, M. G. A. O. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.001 · Cited by 180 · see citing works
Zhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 177 · see citing works
Zhou, Z.-H., Ji, C., Xiao, H., Zhao, H., Cui, Y., & Bian, X. (2017) · Journal of Cancer · doi:10.7150/jca.18466 · Cited by 175 · see citing works
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Šedo, A. (2018) · Frontiers in bioscience · doi:10.2741/4682 · Cited by 162 · see citing works
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 155 · see citing works
Self-citationLavergne, J. M., Juhan-Vague, I., Obert, B., Cherel, G., Meyer, D., Girma, J.-P., Ribba, A., & Ferreira, I. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616142 · Cited by 136 · see citing works
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 90 · see citing works
Thrombosis and von Willebrand Factor
Shahidi, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_122 · Cited by 88 · see citing works
A collagen‐binding EGFR single‐chain Fv antibody fragment for the targeted cancer therapy
Liang, H., Li, X., Chen, B., Wang, B., Zhao, Y., Zhuang, Y., Shen, H., Zhang, Z., & Dai, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.029 · Cited by 54 · see citing works
Multiplex three-dimensional optical mapping of tumor immune microenvironment
Lee, S. S.-Y., Bindokas, V. P., & Kron, S. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-16987-x · Cited by 54 · see citing works
Self-citationBallmer-Weber, B. K., Dummer, R., Küng, E., Burg, G., & Ballmer, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.16 · Cited by 49 · see citing works
A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix
Liang, H., Li, X., Wang, B., Chen, B., Zhao, Y., Sun, J., Zhuang, Y., Shi, J., Shen, H., Zhang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep18205 · Cited by 49 · see citing works
Addi, C., Murschel, F., & Crescenzo, G. D. (2016) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2016.0280 · Cited by 47 · see citing works
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Ishihara, J., Ishihara, A., Potin, L., Hosseinchi, P., Fukunaga, K., Damo, M., Gajewski, T. F., Swartz, M. A., & Hubbell, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0091 · Cited by 44 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296 · see citing works
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · see citing works
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
BackgroundComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735 · see citing works
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 688 · see citing works
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628 · see citing works
The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
Prakash, J., & Shaked, Y. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0002 · Cited by 391 · see citing works
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 229 · see citing works
Self-citationImmune Modulatory Properties of Collagen in Cancer
Rømer, A. M. A., Thorseth, M., & Madsen, D. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791453 · Cited by 231 · see citing works
Engineering cytokine therapeutics
Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., et al. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00030-y · Cited by 223 · see citing works
Natural killer cells: a promising immunotherapy for cancer
Chu, J., Gao, F., Yan, M., Zhao, S., Yan, Z., Shi, B., & Liu, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03437-0 · Cited by 189 · see citing works
Kirchhammer, N., Trefny, M. P., der Maur, P. A., Laubli, H. P., & Zippelius, A. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3605 · Cited by 179 · see citing works
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 173 · see citing works
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Wang, F., Xu, D., Su, H., Zhang, W., Sun, X., Monroe, M. K., Chakroun, R. W., Wang, Z., Dai, W., Oh, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz8985 · Cited by 150 · see citing works
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, W. S., Coleman, I. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37874-2 · Cited by 132 · see citing works
Self-citationEngineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 129 · see citing works
Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127 · see citing works
Self-citationVon Willebrand factor and cancer; metastasis and coagulopathies
Patmore, S., Dhami, S. P. S., & O’Sullivan, J. M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14976 · Cited by 123 · see citing works
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 115 · see citing works
Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy
Jiang, C., Chen, K., Liu, A., Huang, H., Fan, Y.-N., Zhao, D., Ye, Q., Zhang, H., Xu, C., Shen, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21497-6 · Cited by 112 · see citing works
Akkın, S., Varan, G., & Bilensoy, E. (2021) · Molecules · doi:10.3390/molecules26113382 · Cited by 104 · see citing works
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 101 · see citing works
Mansurov, A., Hosseinchi, P., Chang, K., Lauterbach, A. L., Gray, L. T., Alpar, A. T., Budina, E., Slezak, A. J., Kang, S., Cao, S., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00888-0 · Cited by 102 · see citing works
Self-citationCollagen biology making inroads into prognosis and treatment of cancer progression and metastasis
Cavaco, A. C. M., Dâmaso, S., Casimiro, S., & Costa, L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09888-5 · Cited by 101 · see citing works
Multiple roles for basement membrane proteins in cancer progression and EMT
Banerjee, S., Lo, W., Majumder, P., Roy, D., Ghorai, M., Shaikh, N. K., Kant, N., Shekhawat, M. S., Gadekar, V. S., Ghosh, S., et al. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151220 · Cited by 96 · see citing works
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 95 · see citing works
Shen, X., Pan, D., Gong, Q., Gu, Z., & Luo, K. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.017 · Cited by 96 · see citing works
Wang, S., Li, Y., Xu, C., Dong, J., & Wei, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008431 · Cited by 86 · see citing works
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Sasaki, K., Ishihara, J., Ishihara, A., Miura, R., Mansurov, A., Fukunaga, K., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aaw6081 · Cited by 82 · see citing works
Self-citationMaximizing response to intratumoral immunotherapy in mice by tuning local retention
Momin, N., Palmeri, J. R., Lutz, E. A., Jailkhani, N., Mak, H. H., Tabet, A., Chinn, M. M., Kang, B. H., Spanoudaki, V. C., Hynes, R. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27390-6 · Cited by 81 · see citing works
Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
He, Y., Liu, T., Dai, S., Xu, Z., Wang, L., & Luo, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739161 · Cited by 83 · see citing works
Liu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 77 · see citing works
Wang, F., Huang, Q., Su, H., Sun, M., Wang, Z., Chen, Z., Zheng, M., Chakroun, R. W., Monroe, M. K., Chen, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204621120 · Cited by 76 · see citing works
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
Flies, D. B., Langermann, S., Jensen, C., Karsdal, M. A., & Willumsen, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199513 · Cited by 76 · see citing works
Cytokine engineering for targeted cancer immunotherapy
Bonati, L., & Tang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.007 · Cited by 75 · see citing works
Wang, M., Yan, D., Wang, M., Wu, Q., Song, R., Huang, Y., Rao, J., Wang, D., Zhou, F., & Tang, B. Z. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202205371 · Cited by 74 · see citing works
Nanocarriers for cancer nano-immunotherapy
Rana, I., Oh, J., Baig, J., Moon, J. H., Son, S., & Nam, J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01241-3 · Cited by 74 · see citing works
Targeted Drug Delivery via the Use of ECM-Mimetic Materials
Hwang, J., Sullivan, M. O., & Kiick, K. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00069 · Cited by 74 · see citing works
Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy
Strasenburg, W., Jóźwicki, J., Durślewicz, J., Kuffel, B., Parol‐Kulczyk, M., Kowalewski, A., Grzanka, D., Drewa, T. A., & Adamowicz, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909767 · Cited by 73 · see citing works
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement
Chin, A. L., Jiang, S., Jang, E., Niu, L., Li, L., Jia, X., & Tong, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25391-z · Cited by 71 · see citing works
Hydroxyethyl starch based smart nanomedicine
Wang, H., Hu, H., Yang, H., & Li, Z. (2021) · RSC Advances · doi:10.1039/d0ra09663f · Cited by 69 · see citing works
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Lombaerde, E. D., Wever, O. D., & Geest, B. G. D. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188526 · Cited by 69 · see citing works
Targeting Tumors Using Peptides
Scodeller, P., & Asciutto, E. K. (2020) · Molecules · doi:10.3390/molecules25040808 · Cited by 65 · see citing works
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 66 · see citing works
Katsumata, K., Ishihara, J., Mansurov, A., Ishihara, A., Raczy, M. M., Yuba, E., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1971 · Cited by 64 · see citing works
Self-citationProtease-controlled secretion and display of intercellular signals
Vlahos, A. E., Kang, J., Aldrete, C. A., Zhu, R., Chong, L. S., Elowitz, M. B., & Gao, X. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28623-y · Cited by 61 · see citing works
Present Scenario of Bioconjugates in Cancer Therapy: A Review
Wadhawan, A., Chatterjee, M., & Singh, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215243 · Cited by 53 · see citing works
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Kim, J., Lee, K.-J., & Lee, S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.257 · Cited by 51 · see citing works
Self-citationWang, F., Su, H., Wang, Z., Anderson, C. F., Sun, X., Wang, H., Laffont, P., Hanes, J. S., & Cui, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c01748 · Cited by 51 · see citing works
Polymeric materials for immune engineering: Molecular interaction to biomaterial design
Soni, S. S., & Rodell, C. B. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.016 · Cited by 51 · see citing works
Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy
Baldari, S., Modugno, F. D., Nisticò, P., & Toietta, G. (2022) · Cancers · doi:10.3390/cancers14194706 · Cited by 50 · see citing works
Wang, Y., Li, W., Li, Z., Mo, F., Chen, Y., Iida, M., Wheeler, D. L., & Hu, Q. (2023) · Science Advances · doi:10.1126/sciadv.adf6854 · Cited by 49 · see citing works
Qu, Y., Dunn, Z. S., Chen, X., MacMullan, M. A., Cinay, G. E., Wang, H.-Y., Liu, J., Hu, F., & Wang, P. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.050 · Cited by 47 · see citing works
Biomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 48 · see citing works
Luo, J., Zhang, Z., Zeng, Y., Dong, Y., & Ma, L. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117964 · Cited by 47 · see citing works
Understanding the matrix: collagen modifications in tumors and their implications for immunotherapy
Borst, R., Meyaard, L., & Ramos, M. I. P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05199-3 · Cited by 45 · see citing works
Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma
Morrell, M. B. G., Alvarez‐Florez, C., Zhang, A., Kleinerman, E. S., Savage, H., Marmonti, E., Park, M., Shaw, A., & Schadler, K. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27835 · Cited by 45 · see citing works
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 43 · see citing works
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Rawla, P., Barsouk, A. A., Hadjinicolaou, A. V., & Barsouk, A. (2019) · Medical Sciences · doi:10.3390/medsci7080083 · Cited by 45 · see citing works
Improving safety of cancer immunotherapy via delivery technology
Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120407 · Cited by 43 · see citing works
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42 · see citing works
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
Uricoli, B., Birnbaum, L. A., Do, P., Kelvin, J., Jain, J., Costanza, E., Chyong, A., Porter, C. C., Rafiq, S., & Dreaden, E. C. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002214 · Cited by 42 · see citing works
Switchable immune modulator for tumor-specific activation of anticancer immunity
Zhao, Y., Xie, Y., Herck, S. V., Nassiri, S., Gao, M., Guo, Y., & Tang, L. (2021) · Science Advances · doi:10.1126/sciadv.abg7291 · Cited by 42 · see citing works
Wang, F., Su, H., Xu, D., Monroe, M. K., Anderson, C. F., Zhang, W., Oh, R., Wang, Z., Sun, X., Wang, H., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121182 · Cited by 42 · see citing works
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Henze, J., Tacke, F., Hardt, O., Alves, F., & Rawashdeh, W. A. (2020) · Cancers · doi:10.3390/cancers12061389 · Cited by 40 · see citing works
Manna, S., Maiti, S., Shen, J., Weiss, A. M., Mulder, E. J., Du, W., & Esser-Kahn, A. P. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122062 · Cited by 39 · see citing works
Battistella, C., Liang, Y., & Gianneschi, N. C. (2021) · Advanced Materials · doi:10.1002/adma.202007504 · Cited by 39 · see citing works
Harnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 38 · see citing works
Willumsen, N., Jensen, C., Green, G. A., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04226-0 · Cited by 37 · see citing works
Closset, L., Gultekin, O., Salehi, S., Sarhan, D., Lehti, K., & Gonzalez‐Molina, J. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.07.003 · Cited by 35 · see citing works
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34 · see citing works
The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer
Colonne, C. K., Favaloro, E. J., & Pasalic, L. (2022) · Healthcare · doi:10.3390/healthcare10030557 · Cited by 33 · see citing works
Nano drug delivery systems: a promising approach to scar prevention and treatment
Ding, J.-Y., Sun, L., Zhu, Z.-H., Wu, X., Xu, X., & Xiang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02037-4 · Cited by 35 · see citing works
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9879 · Cited by 33 · see citing works
Self-citationEngineering Targeting Materials for Therapeutic Cancer Vaccines
Briquez, P. S., Hauert, S., de Titta, A., Gray, L. T., Alpar, A. T., Swartz, M. A., & Hubbell, J. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00019 · Cited by 32 · see citing works
Self-citationOvercoming biological barriers to improve solid tumor immunotherapy
Ukidve, A., Cu, K., Kumbhojkar, N., Lahann, J., & Mitragotri, S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00923-8 · Cited by 33 · see citing works
Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors
Thorlacius‐Ussing, J., Jensen, C., Madsen, E. A., Nissen, N. I., Manon‐Jensen, T., Chen, I. M., Johansen, J. S., Diab, H. M. H., Jørgensen, L. N., Karsdal, M. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084144 · Cited by 32 · see citing works
Mu, J., Du, Y., Li, X., Yan, R., Zhong, H., Cai, M., Yu, N. H., Zhang, J., Yuan, X., Hua, X., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138554 · Cited by 32 · see citing works
Qin, Y., Wang, G., Chen, L., Sun, Y., Yang, J., Piao, Y., Shen, Y., & Zhou, Z. (2023) · Advanced Materials · doi:10.1002/adma.202302292 · Cited by 30 · see citing works
Park, S., Oh, J. H., Park, D. J., Zhang, H., Noh, M., Kim, Y., Kim, Y.-S., Kim, H., Kim, Y., Ha, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620166 · Cited by 30 · see citing works
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., & Cui, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601497 · Cited by 29 · see citing works
Aghlara-Fotovat, S., Nash, A., Kim, B., Krencik, R., & Omid Veiseh, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01018-0 · Cited by 27 · see citing works
The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance
Fromme, J. E., & Zigrino, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.864302 · Cited by 27 · see citing works
Liu, J., Meng, Z., Xu, T., Kuerban, K., Wang, S., Zhang, X., Fan, J., Ju, D., Tian, W., Huang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845217 · Cited by 27 · see citing works
Nanomedicine for Acute Brain Injuries: Insight from Decades of Cancer Nanomedicine
Kandell, R. M., Waggoner, L. E., & Kwon, E. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00287 · Cited by 26 · see citing works
Kandell, R. M., Kudryashev, J. A., & Kwon, E. J. (2021) · ACS Nano · doi:10.1021/acsnano.1c09064 · Cited by 26 · see citing works
Advancements and challenges in immunocytokines: A new arsenal against cancer
Shi, W., Liu, N., & Lu, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.024 · Cited by 25 · see citing works
Targeting collagen to optimize cancer immunotherapy
Wang, Y., Zhang, F., Qian, Z., Ying, J., Wu, D., Liu, L., Ning, X., Mei, J., Chen, D., & Zhang, Y. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00691-y · Cited by 25 · see citing works
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H., & Slaney, C. Y. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab016 · Cited by 24 · see citing works
Intratumorally anchored cytokine therapy
Wittrup, K. D., Kaufman, H. L., Schmidt, M. M., & Irvine, D. J. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2084070 · Cited by 25 · see citing works
Collado, J., Boland, L. K., Ahrendsen, J. T., Miska, J. M., & Lee-Chang, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336476 · Cited by 25 · see citing works
Immunoengineering approaches for cytokine therapy
Mansurov, A., Lauterbach, A. L., Budina, E., Alpar, A. T., Hubbell, J. A., & Ishihara, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00515.2020 · Cited by 23 · see citing works
Self-citationRemodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 28 · see citing works
Synthetic Tuning of Domain Stoichiometry in Nanobody–Enzyme Megamolecules
Metcalf, K. J., Kimmel, B. R., Sykora, D. J., Modica, J. A., Parker, K. A., Berens, E. B., Dai, R., Dravid, V. P., Werb, Z., & Mrksich, M. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00578 · Cited by 22 · see citing works
Engineering multi-specific nano-antibodies for cancer immunotherapy
Fan, Y.-N., Zhu, L., Qing, Y.-X., Ye, S.-Y., Ye, Q., Huang, X., Zhao, D., Tian, T.-Y., Li, F.-C., Yan, G.-R., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01425-5 · Cited by 21 · see citing works
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009541 · Cited by 21 · see citing works
Self-citationManna, S., Maiti, S., Shen, J., Du, W., & Esser-Kahn, A. P. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c01001 · Cited by 21 · see citing works
Overcoming the limitations of cytokines to improve cancer therapy
Trani, C. A. D., Cirella, A., Arrizabalaga, L., Fernández-Sendin, M., Bella, Á., Aranda, F., Melero, I., & Berraondo, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.05.002 · Cited by 20 · see citing works
Lozeau, L. D., Grosha, J., Smith, I. M., Stewart, E. J., Camesano, T. A., & Rolle, M. W. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00227 · Cited by 20 · see citing works
Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview
Boersma, B., Poinot, H., & Pommier, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16080974 · Cited by 19 · see citing works
- Authors
- Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., Raczy, M. M., Gray, L. T., Mansurov, A., Katsumata, K., Fukayama, M., Kron, S. J., Swartz, M. A., & Hubbell, J. A.
- Affiliations
- University of Chicago (US)
- Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, IL 60637, USA.
- The University of Tokyo (JP)
- Department of Pathology, University of Tokyo, 113-8655 Tokyo, Japan.
- Corresponding author
- Ishihara, Jun
- Ishihara, Ako
- Katsumata, Kiyomitsu
- Hubbell, Jeffrey A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-04-10
- Volume
- 11
- Issue
- 487
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6541444
- OpenAlex
- W2939112943
- Cited by
- 190
- References
- 49
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 20 · 2023: 30 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 12
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Cancer Institute (CA199663)
- National Institute of Biomedical Imaging and Bioengineering (EB022636)
- European Research Commission grant (Cytrix)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, cytokine therapy, interleukin-2, antibody-drug conjugates, breast cancer, tumor targeting, combination therapy, orthotopic tumor model
- MeSH terms
- Protein Domains, Animals, Antibodies, Neoplasm, Collagen, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Immunity, Immunotherapy, Injections, Intravenous, Interleukin-2, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Cytokines, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
